Bf Biosciences Ltd · PSX:BFBIO
Bf Biosciences — Investor Presentation (November 2024)
19 slides from Bf Biosciences's investor presentation, Nov 27, 2024
Slide 1: Corporate Briefing Session
Corporate Briefing Session Wednesday, November 27, 2024
Slide 2: Agenda overview
01. Company Profile 04. Financial Performance 02. Product Portfolio 05. Expansion Update 03. Pharmaceutical Industry 06. Question & Answers Session Highlights
Slide 3: Agenda
AGENDA 1. Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Expansion Update 6 Questions and Answers Session PAGE 3
Slide 4: Incorporation, Founding Sponsors, ISO Certifications, Principle Business
Incorporation Founding ISO Principle Sponsors Certifications Business Incorporated in 2006 Joint venture ISO 9001, 45000 and Primarily Engaged in as Public Unlisted between Grupo 14001 the Imports, Company, Empresarial Bagó S.A Certified. Manufacture and Subsequently listed and Ferozsons Sale of on
Slide 5: Founding sponsors: Bagó and Ferozsons
Bagó was incorporated in Argentina in 1934. It was Ferozsons (PSX: FEROZ) is a public limited the first company to manufacture penicillin-based company founded in the year 1956 and is also products in Argentina in 1945. listed on the Pakistan Stock Exchange. Bagó is a diversified group engaged in va
Slide 6: Company milestones timeline
Financial Close Commissioning of Line II of Brownfield Implementation of Start of Local Expansion SAP S/4 HANA Listing on PSX Manufacturing 2009 2021 2023 2024 2006 2020 2021 2023 BFBIO Finalization of PESA Award for Launch of: Incorporated, Licensing Agreement Export of Remdesivir i. Etanercept in
Slide 7: Facility and Line I and Line II capacities
Premium High-Speed Large Volume High-Speed Technology Combi Line Lyophilizer Line Pre-filled Syringes Plant Location 5 KM - Sunder Raiwind Road, Lahore State of the Art Infrastructure Germany Spain Germany Line I and Line II Capacities (Daily Units) Facility Pioneering Designed as per Biotech Facili
Slide 8: Agenda
AGENDA 1. Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Expansion Update 6 Questions and Answers Session PAGE 8
Slide 9: Product Portfolio: Key Brands
Product Portfolio BYF BIOSCIENCES Key Brands in Portfolio ERITROGEN Erythropo pressin acetate) nova Fer Stren or rence PRESCRTIONONY ee ony Semati eels latideC oxF Etern (ETANERCEPT) Innovotor' Specs Solution oriection forSubcotaneous S005 Only prescription only R, Only ZOBAR (AZITHROMYCIN TABLETS U
Slide 10: Agenda
AGENDA 1. Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Expansion Update 6 Questions and Answers Session PAGE 10
Slide 11: Retail Pharmaceutical Business in Pakistan
Retail Pharmaceutical Business in Pakistan Global Pharma Industry The pharmaceutical sector continues to thrive, propelled by its integral role in addressing global healthcare needs and improving patient outcomes. Industry Structure Leading global firms control R&D and patent ownership, while smalle
Slide 12: Agenda
AGENDA 1. Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Expansion Update 6 Questions and Answers Session PAGE 12
Slide 13: Income Statement FY 2024
INCOME 4,000 3,659 1,800 STATEMENT 3,500 1,600 1,533 3,000 1,400 1,200 2,500 PKR 3,659 Mn+ 102% 2,000 1,810 1,000 REVENUE – FY 2024 YoY 1,500 800 600 450 1,000 400 PKR 385 Mn+ 159% 500 200 NPAT - FY 2024 YoY 0 0 Revenue Gross Profit FY 23 FY 24 FY 23 FY 24 GROSS MARGIN 42% 450 900 385 769 400 800 35
Slide 14: Income Statement 3MFY 2025
INCOME 1,600 600 564 STATEMENT 1,400 1,386 500 1,200 965 378 400 1,000 PKR 1,386 Mn+ 44% 800 300 REVENUE – 3MFY 2025 YoY 600 200 400 PKR 115 Mn+ 14% 200 100 NPAT - 3MFY 2025 YoY 0 0 Revenue Gross Profit 3MFY 24 3MFY 25 3MFY 24 3MFY 25 GROSS MARGIN 41% 120 240 237 115 NET PROFIT 115 235 MARGIN 8% 230
Slide 15: Agenda
AGENDA 1. Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Expansion Update 6 Questions and Answers Session PAGE 15
Slide 16: Expansion Update
Expansion Update PAGE16
Slide 17: Expansion
Expansion PAGE17
Slide 18: Agenda
AGENDA 1. Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Expansion Update 6 Questions and Answers Session PAGE 18
Slide 19: Thank You
Wer ey PLL qee62 THANK YOU
BF Biosciences — Investor Presentation (November 2024) on 6ix